La société biopharmaceutique danoise Tetra Pharm Technologies est fière d’annoncer une étape importante dans le domaine de la recherche sur la suppression de l’appétit, grâce au développement d’un composé novateur s’appuyant sur sa plate-forme technologique innovante. COPENHAGUE, Danemark, 8 février 2024 /PRNewswire/ — Après avoir déposé avec succès une demande de propriété intellectuelle (PI) en… Continue reading Tetra Pharm Technologies procède à des essais précliniques sur l’antagoniste CB1, appelé TPT0701, destiné à la suppression de l’appétit
Category: Newswire
Tetra Pharm Technologies avanza el antagonista de CB1, TPT0701, para la supresión del apetito
-Tetra Pharm Technologies avanza el antagonista de CB1, TPT0701, para la supresión del apetito en pruebas preclínicas La empresa biofarmacéutica danesa Tetra Pharm Technologies se enorgullece de anunciar un hito importante en el ámbito de la investigación sobre la supresión del apetito al desarrollar un compuesto de vanguardia aprovechando su innovadora plataforma tecnológica. COPENHAGUE, Dinamarca,… Continue reading Tetra Pharm Technologies avanza el antagonista de CB1, TPT0701, para la supresión del apetito
Tetra Pharm Technologies advances CB1 antagonist, TPT0701, for appetite suppression into preclinical testing
The Danish biopharmaceutical company, Tetra Pharm Technologies, proudly announces a significant milestone in the realm of appetite suppression research having developed a cutting-edge compound leveraging their innovative platform technology. COPENHAGEN, Denmark, Feb. 8, 2024 /PRNewswire/ — Following the successful filing of Intellectual Property (IP) for their applied platform technology targeting the endocannabinoid system (ECS), Tetra… Continue reading Tetra Pharm Technologies advances CB1 antagonist, TPT0701, for appetite suppression into preclinical testing
Tetra Pharm Technologies advances CB1 antagonist, TPT0701, for appetite suppression into preclinical testing
The Danish biopharmaceutical company, Tetra Pharm Technologies, proudly announces a significant milestone in the realm of appetite suppression research having developed a cutting-edge compound leveraging their innovative platform technology. COPENHAGEN, Denmark, Feb. 8, 2024 /PRNewswire/ — Following the successful filing of Intellectual Property (IP) for their applied platform technology targeting the endocannabinoid system (ECS), Tetra… Continue reading Tetra Pharm Technologies advances CB1 antagonist, TPT0701, for appetite suppression into preclinical testing
Jak může Decun změnit L2 Etherea: Pozice společnosti CoinEx Research
HONGKONG, 8. února 2024 /PRNewswire/ – Před aktivací mainnetu Cancun-Deneb (neboli Dencun), nejočekávanějšího upgradu Etherea v roce 2024, popisuje společnost CoinEx jeho hlavní prvky. Proto-Danksharding, bloby, KZG: Co v sobě ukrývá Dencun Odborníci ze společnosti CoinEx popsali Dencun jako významný upgrade Etherea (ETH), který má zahrnovat pět EIP, mezi nimiž se největší pozornosti trhu těší EIP-4844.… Continue reading Jak může Decun změnit L2 Etherea: Pozice společnosti CoinEx Research
NORDEN reports annual result of USD 400 million for 2023 and continues to return cash to shareholders
ANNOUNCEMENT NO. 29 – 8 FEBRUARY 2024 COPENHAGEN, Denmark, Feb. 8, 2024 /PRNewswire/ — NORDEN reports an annual result of USD 400 million (approx. DKK 2,760 million). For the fourth quarter of 2023 net profit amounted to USD 43 million (approx. DKK 297 million). Freight Services & Trading posted a net profit of USD 133… Continue reading NORDEN reports annual result of USD 400 million for 2023 and continues to return cash to shareholders
DIAMOND OFFSHORE ANNOUNCES NEW FLOATER COMMITMENTS
HOUSTON, Feb. 8, 2024 /PRNewswire/ — Diamond Offshore Drilling, Inc. (NYSE: DO) today announced that it has executed a two-year contract extension with a subsidiary of bp in the U.S. Gulf of Mexico for the Ocean BlackLion, commencing in September 2024 in direct continuation of the rig’s current contract. This contract extension represents approximately $350 million… Continue reading DIAMOND OFFSHORE ANNOUNCES NEW FLOATER COMMITMENTS
NORDEN reports annual result of USD 400 million for 2023 and continues to return cash to shareholders
ANNOUNCEMENT NO. 29 – 8 FEBRUARY 2024 COPENHAGEN, Denmark, Feb. 8, 2024 /PRNewswire/ — NORDEN reports an annual result of USD 400 million (approx. DKK 2,760 million). For the fourth quarter of 2023 net profit amounted to USD 43 million (approx. DKK 297 million). Freight Services & Trading posted a net profit of USD 133… Continue reading NORDEN reports annual result of USD 400 million for 2023 and continues to return cash to shareholders
XNK Therapeutics to present at Redeye Regenerative Medicine/Cell Therapy event
HUDDINGE, Sweden, Feb. 8, 2024 /PRNewswire/ — XNK Therapeutics AB (“XNK”) today announced that Johan Liwing, CEO, will present the company at the Redeye Regenerative Medicine/Cell Therapy event on February 14. XNK’s presentation starts at 10:45 CET. The event will be broadcasted live starting at 09:00 CET and can be followed on Redeye’s homepage. XNK’s… Continue reading XNK Therapeutics to present at Redeye Regenerative Medicine/Cell Therapy event
XNK Therapeutics to present at Redeye Regenerative Medicine/Cell Therapy event
HUDDINGE, Sweden, Feb. 8, 2024 /PRNewswire/ — XNK Therapeutics AB (“XNK”) today announced that Johan Liwing, CEO, will present the company at the Redeye Regenerative Medicine/Cell Therapy event on February 14. XNK’s presentation starts at 10:45 CET. The event will be broadcasted live starting at 09:00 CET and can be followed on Redeye’s homepage. XNK’s… Continue reading XNK Therapeutics to present at Redeye Regenerative Medicine/Cell Therapy event